Otitis media therapy and drug resistance part 2: Current concepts and new directions

Infections in Medicine

Volumn 18, Issue 5, 2001, Pages 263-270

  Leibovitz, Eugene ^a   Dagan, Ron ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Antibiotic resistance; Haemophilus influenzae; Otitis media, acute; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFACLOR; CEFIXIME; CEFPODOXIME; CEFPODOXIME PROXETIL; CEFPROZIL; CEFTIBUTEN; CEFTRIAXONE; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CLEACIN; CLINDAMYCIN; CLINDAMYCIN PHOSPHATE; COTRIMOXAZOLE; LORACARBEF; MACROLIDE; PEDIAZOLE; STREPTOCOCCUS VACCINE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; HUMAN; OTITIS MEDIA; REVIEW; STREPTOCOCCUS PNEUMONIAE;

EID: 0035012013     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Faden H, Stanievich J, Brodsky L, et al. Changes in nasopharyngeal flora during otitis media of childhood. Pediatr Infect Dis J. 1990; 9:623-626.
2. Zenni MK, Cheatham SH, Thompson JM, et al. Streptococcus pneumoniae colonization in the young child: association with otitis media and resistance to penicillin. J Pediatr. 1995;127:533-537.
3. Ghaffar F, Friedland IR, McCracken GH Jr. Dynamics of nasopharyngeal colonization by Streptococcus pneumoniae. Pediatr Infect Dis J. 1999;18:638-646.
4. Anianson G, Alm B, Anderson B, et al. Nasopharyngeal colonization during the first year of life. J Infect Dis. 1992;165(suppl):S38-S41.
5. Dagan R, Melamed R, Muallem M, et al. Nasopharyngeal colonization in southern Israel with antibiotic-resistant pneumococci during the first 2 years of life: relation to serotypes likely to be included in pneumococcal conjugate vaccines. J Infect Dis. 1996;174:1352-1355.
6. Reichler MR, Allphin AA, Breiman RF, et al. The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio. J Infect Dis. 1992;166:1346-1353.
7. Yagupsky P, Porat N, Prajgrod F, et al. Acquisition, carriage and transmission of pneumococci with decreased antibiotic susceptibility in young children attending a day-care facility in southern Israel. J Infect Dis. 1998;177:1003-1012.
8. Givon-Lavi N, Dagan R, Fraser D, et al. Marked differences in pneumococcal carriage and resistance patterns between day care centers located within a small area. Clin Infect Dis. 1999; 29:1274-1280.
9. Cohen R, Bingen E, Varon E, et al. Change in nasopharyngeal carriage of Streptococcus pneumoniae resulting from antibiotic therapy for acute otitis media. Pediatr Infect Dis J. 1997;16: 555-560.
10. Dagan R, Leibovitz E, Greenberg D, et al. Dynamics of pneumococcal nasopharyngeal colonization during the first days of antibiotic treatment in pediatric patients. Pediatr Infect Dis J. 1998;17:880-885.
11. Dagan R, Leibovitz E, Piglansky L, Yagupsky P. Effect of antibiotic treatment on pneumococcal nasopharyngeal carriage during and after acute otitis media: comparison of three oral drugs. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco. Abstract 1028.
12. Dagan R, Leibovitz E, Cheletz G. Antibiotic treatment in acute otitis media induces middle ear fluid super-infection with pre-existing nasopharyngeal antibiotic-resistant S. pneumoniae. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco. Abstract 1184.
13. Cohen R, Levy C, de La Rocque F, et al. Nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae (Sp) increases the risk of antibiotic treatment failures in acute otitis media (AOM). In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-20, 1995; San Francisco. Abstract C6.
14. Leibovitz E, Raiz S, Piglansky L, et al. The bacteriologic and clinical efficacy of trimethoprim/sulfamethoxazole in the treatment of acute otitis media. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29,1999; San Francisco. Abstract 778.
15. Eldan M, Leibovitz E, Piglansky L, et al. Predictive value of pneumococcal nasopharyngeal cultures for the assessment of non-responsive acute otitis media in children. Pediatr Infect Dis J. 2000;19:298-303.
16. Gehanno P, Leonir G, Barry B, et al. Evaluation of nasopharyngeal cultures for bacteriologic assessment of acute otitis media in children. Pediatr Infect Dis J. 1996;15:329-332.
17. Dagan R, Shvartzman P, Liss Z. Variation in acceptance of common oral antibiotic suspensions. Pediatr Infect Dis J. 1994;13:686-690.
18. Canafax DM, Yuan Z, Chonmaitree T, et al. Amoxicillin middle ear fluid penetration and pharmaokinetics in children with acute otitis media. Pediatr Infect Dis J. 1998;17:149-156.
19. Krause PJ, Owens NJ, Nightingale CH, et al. Penetration of amoxicillin, cefaclor, erythromycin-sulfisoxazole, and trimethoprim-sulfamethoxazole into the middle ear fluid of pa-tients with chronic serous otitis media. J Infect Dis. 1982;145:815-821.
20. Seikel K, Shelton S, McCracken GH Jr. Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media. Pediatr Infect Dis J. 1997;16:710-711.
21. Nelson CT, Mason EO Jr, Hedrick JA, et al. Penicillin-resistant Streptococcus pneumoniae: implications for treatment. Pediatr Infect Dis J. 1994;13:585-589.
22. Lister PD, Pong A, Chartrand SA, Sanders CC. Rationale behind high-dose amoxicillin therapy for acute otitis media due to penicillin-non-susceptible pneumococci: support from in vitro pharmacodynamic studies. Antimicrob Agents Chemother. 1997;41:1926-1932.
23. Pankuch GA, Jacobs MR, Appelbaum PC. Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother. 1995;35: 883-888.
24. Doit C, Loukil C, Fitoussi F, et al. Emergence in France of multiple clones of clinical Streptococcus pneumoniae isolates with high-level resistance to amoxicillin. Antimicrob Agents Chemother. 1999;43:1480-1483.
25. Behre U, Burrow HM, Quinn P, et al. Efficacy of twice-daily dosing of amoxicillin-clavulanate in acute otitis media in children. Infection. 1997; 25:163-166.
26. Hoberman A, Paradise J, Burch D, et al. Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin) for the treatment of acute otitis media. Peidiatr Infect Dis J. 1997;16:463-170.
27. Dagan R, Johnson C, McLinn S, et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J. 2000;19:95-104.
28. Dagan R, Hoberman A, Leibovitz E, et al. Bacteriologic and clinical efficacy of a new amoxicillin/clavulanate in the treatment of acute otitis media. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto. Abstract 107.
29. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics in making choices for the management of otitis media. Pediatr Infect Dis J. 1996;15:255-259.
30. Dagan R, Abramson O, Leibovitz E, et al. Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin. Pediatr Infect Dis J. 1996;15:980-985.
31. Leibovitz E, Abramson O, Greenberg D, et al. Correlation between MlC values and bacteriologie outcome in pneumococcal acute otitis media. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 16-19, 1996; New Orleans. Abstract LM59.
32. Dagan R, Abramson O, Leibovitz E, et al. Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of otitis media? J Infect Dis. 1997;176:1253-1259.
33. Dagan R, Piglansky L, Yagkupsky P, et al. Bacteriologic response to acute otitis media: comparison between azythromycin, cefaclor and amoxicillin. In: Program and abstracts of the 37th International Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto. Abstract K-103.
34. van Dyk JC, Terespolsky SA, Meyer CS, et al. Penetration of cefpodoxime into middle ear fluid in pediatric patients with acute otitis media. Pediatr Infect Dis J. 1997;16:79-81.
35. Pichichero ME, McLinn S, Aronovitz G, et al. Cefprozil treatment of persistent and recurrent acute otitis media. Pediatr Infect Dis J. 1997;16: 471-478.
36. Gudnason T, Gudbrandsson F, Barsanti F, Kristinsson KG. Penetration of ceftriaxone into the middle ear fluid of children. Pediatr Infect Dis J. 1998;17:238-260.
37. Leibovitz E, Piglansky L, Raiz S, et al. Bacteriologic and clinical efficacy of one-day vs. three-day intrammuscular ceftriaxone for treatment of nonresponsive acute otitis media. Pediatr Infect Dis J. 2000;19:1040-1045.
38. Gehanno P, Nguyen L, Barry B, et al. Eradication by ceftriaxone of Streptococcus pneumoniae isolates with increased resistance to penicillin in cases of acute otitis media. Antimicrob Agents Chemother. 1999;43:16-20.
39. Leibovitz E, Piglansky L, Raiz S, et al. Bacteriological and clinical efficacy of 1-day versus 3-day intramuscular ceftriaxone in the treatment of nonresponsive acute otitis media. Pediatr Infect Dis J. 2000;19(suppl):S47-S56.
40. Appelbaum PC. Epidemiology and in vitro susceptibility of drug-resistant Streptococcus pneumoniae. Pediatr Infect Dis J. 1996;15:932-934.
41. Jacobs MR. Increasing importance of antibiotic-resistant Streptococcus pneumoniae in acute otitis media. Pediatr Infect Dis J. 1996;15:940-943.
42. Jacobs MR, Dagan R, Appelbaum PC, Burch DJ. Prevalence of antimicrobial-resistant pathogens in middle ear fluid: multinational study of 917 children with acute otitis media. Antimicrob Agents Chemother. 1998;42:589-595.
43. Dowell SF, Butler JC, Giebink SG, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance - a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J. 1999;18:1-9.
44. McCarty J. A multicenter, open label trial of azithromycin for the treatment of children with acute otitis media. Pediatr Infect Dis J. 1996;15(9 suppl)S10-S14.
45. Rodriguez AF. An open study to compare azithromycin with cefaclor in the treatment of children with acute otitis media. J Antimicrob Chemother. 1996;37(suppl C):63-69.
46. McLinn S. A multicenter, double blind comparison of azithromycin and amoxicillin/clavulanate for the treatment of acute otitis media in children. Pediatr Infect Dis J. 1996;15(suppl)S20-S23.
47. Dagan R, Leibovitz E, Jacobs M, et al. Bacteriologic response in acute otitis media caused by Haemophilus influence treated with azithromycin. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 4, 1997; Toronto. Abstract K 102.
48. Dagan R, Leibovitz E, Fliss DM, et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother. 2000;44:43-50.
49. Scaglione F. Predicting the clinical efficacy of antibiotics: toward definitive criteria. Pediatr Infect Dis J. 1997;16(suppl):S56-S59.
50. Howie VM. Eradication of bacterial pathogens from middle ear infections. Clin Infect Dis. 1992; 14:(suppl2):209-210.
51. Pichichero ME, Cohen R. Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis. Pediatr Infect Dis J. 1997;16:680-695.
52. Klein JO. Review of consensus reports on management of acute otitis media. Pediatr Infect Dis J. 1999;18:1152-1155.
53. Cohen R, Levy C, Boucherat M, et al. Five vs. ten days of antibiotic therapy for acute otitis media in young children. Pediatr Infect Dis J. 2000;19:458-463.
54. Klein JO. Preventing recurrent otitis: what role for antibiotics? Contemp Pediatr. 1994;11:44-60.
55. Principi N, Marchisio P, Massironi E, et al. Prophylaxis of recurrent acute otitis media and middle ear effusion: comparison of amoxicillin with sulfamethoxazole and trimethoprim. Am J Dis Child. 1989;143:1414-1418.
56. Williams RL, Chalmers TC, Stange KC, et al. Use of antibiotics in preventing recurrent acute otitis media and in treating otitis media with effusion. JAMA. 1993;70:1344-1351.
57. Dowell SF, Marcy SM, Phillips WR, et al. Otitis media: principles of judicious use of antimicrobial agents. Pediatrics. 1998;101(suppl, pt 2):165-171.
58. Brook I, Gober AE. Prophylaxis with amoxicillin or sulfisoxazole for otitis media: effect on the recovery of penicillin-resistant bacteria from children. Clin Infect Dis. 1006;22;143-145.
59. Klein JO, Bluestone CD. Acute otitis media. Pediatr Infect Dis. 1982;1:66-73.
60. Klein JO. Nonimmune strategies for prevention of otitis media. Pediatr Infect Dis J. 2000;19 (suppl)S89-S92.
61. Zopf D, Roth S. Oligosaccharide anti-infective agents. Lancet. 1996;347:1017-1021.
62. Uhari M, Kontiokari T, Koskela M, Niemela M. Xylitol chewing gum in prevention of acute otitis media: double blind randomized trial. BMJ. 1996;13:1180-1184.
63. Uhari M, Kontiokari T, Niemela M. Anovel use of xylitol sugar in preventing acute otitis media. Pediatrics. 1998;102:879-884.
64. Eskola J. Immunogenicity of pneumococcal conjugate vaccines. Pediatr Infect Dis J. 2000;19: 388-393.
65. Dagan R, Melamed R, Muallem M, et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis. 1996;174:1271-1278.
66. Dagan R, Muallem M, Melamed R, et al. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr Infect Dis J. 1997;16:1060-1064.
67. Dagan R, Fraser D. Conjugate pneumococcal vaccine and antibiotic-resistant Streptococcus pneumoniae: herd immunity and reduction of otitis morbidity. Pediatr Infect Dis J. 2000;19 (suppl)S79-S88.
68. 197 conjugate pneumococcal vaccine (Pnc-CRM9). In: Program and abstracts of the 18th Annual Meeting of the European Society for Paediatric Infectious Diseases; May 3-5, 2000; Noordwijk, the Netherlands. Abstract O-12.
69. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19:187-195.
70. Eskola J, Kilpi T, and the Finnish Otitis Media (FinOM) Study Group. Efficacy of a heptavalent pneumococcal conjugate vaccine (Pnc-CRM) against serotype-specific, culture-confirmed pneumococcal acute otitis media (AOM) in infants and children. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco. Abstract LB-13.
71. Kilpi T, Jokinen J, Herva E, et al. Effect of a heptavalent pneumococcal conjugate vaccine (PNC-CRM) on pneumococcal acute otitis media (AOM) by serotype. In: Program and abstracts of the 2nd International Symposium on Pneumococci and Pneumococcal Diseases; March 19-23, 2000; Sun City, South Africa. Abstract O-20.
72. 197 vaccine has a major impact on morbidity and antibiotic use in day care centers. Presented at:Year 2000 Pediatric Academic Societies and American Academy of Pediatrics Joint Meeting; May 12-16, 2000; Boston.
73. van Buchem FL, Dunk JH, van't Hof MA. Therapy of acute otitis media: myringotomy, antibiotics, or neither? Lancet. 1981;2:883-887.
74. Nelson CT, Mason EO Jr, Kaplan SL. Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant Streptococcus pneumonia?: implications for treatment. Pediatr Infect Dis J. 1994;13:585-589.
75. Blumer JL. Implications of pharmacokinetics in making choices for the management of acute otitis media. Pediatr Infect Dis J. 1998;17:565-570.
76. Craig WA. Pharmacokinetics/pharmacodynamics parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998; 16:1-12.
77. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995; 22:89-96.